Lilly CEO Plans Dozen-Plus ‘Unmet Needs’ Drugs In China Next Five Years
This article was originally published in PharmAsia News
Eli Lilly & Co. plans to launch more than a dozen drugs in China over the next five years as part of an effort to become the nation’s fastest-growing drug maker.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.